Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR ; volume:31 ; number:1 ; day:18 ; month:8 ; year:2012 ; pages:1-10 ; date:12.2012
Journal of experimental & clinical cancer research ; 31, Heft 1 (18.8.2012), 1-10, 12.2012
- Urheber
-
Wang, Fen
Wang, Shuhang
Wang, Zhijie
Duan, Jianchun
An, Tongtong
Zhao, Jun
Bai, Hua
Wang, Jie
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-9966-31-65
- URN
-
urn:nbn:de:101:1-2019070423064373408634
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Fen
- Wang, Shuhang
- Wang, Zhijie
- Duan, Jianchun
- An, Tongtong
- Zhao, Jun
- Bai, Hua
- Wang, Jie
- SpringerLink (Online service)
Ähnliche Objekte (12)
Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Qualitative Analyse im Rahmen qualitativen und modellbasierten Schliessens
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations